Komentář k článku
Biosimilární infliximab v terapii anti-TNF naivních pacientů s IBD – jednoleté klinické sledování

English version

Autoři: P. D. R. Higgins
Působiště autorů: Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA
Vyšlo v časopise: Gastroent Hepatol 2017; 71(4): 323-324
Kategorie: Komentář
doi: https://doi.org/10.14735/amcsnn2017323

Zdroje

1. Kolar M, Duricova D, Bortlik M et al. Biosimilar infliximab in anti-TNF-naïve IBD patients –⁠ 1-year clinical follow-up. Gastroent Hepatol 2016; 70 (6): 514–522. doi: 10.14735/amgh2016514.

2. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256 (5517): 495–497.

3. Biocompare. [online]. Available from: www.biocompare.com.

4. Cauchi R. State laws and legislation related to biologic medications and substitution of biosimilars. [online]. Available from: www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-and-substitution-of-biosimilars.aspx.

5. Gibson DJ, Heetun ZS, Redmond CE et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13 (2): 330–335. doi: 10.1016/j.cgh.2014. 07.041.

6. Colombel JF, Reinisch W, Mantzaris GJ et al. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn’s disease –⁠ a SONIC post hoc analysis. Aliment Pharmacol Ther 2015; 41 (8): 734–746. doi: 10.1111/apt.13139.

7. Bouguen G, Levesque BG, Pola S et al. Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2014; 20 (2): 231–239. doi: 10.1097/01.MIB.0000437985.00190.aa.

8. Reinink AR, Lee TC, Higgins PD. Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: a meta-analysis. Inflamm Bowel Dis 2016; 22 (8): 1859–1869. doi: 10.1097/ MIB.0000000000000816.

9. Gisbert JP, Bermejo F, Pérez-Calle JL et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 2009; 15 (8): 1190–1198. doi: 10.1002/ibd.20933.